Form 4: Belite Bio Insider Sells Shares Under 10b5-1 Plan

Belite Bio's Chief Scientific Officer, Nathan L. Mata, reported the sale of American depositary shares under a pre-arranged trading plan.

Summary

• Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., reported the sale of American depositary shares (ADS) on May 1, 2026.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025.
• A total of 1,012 ADS were sold across multiple transactions with weighted average prices ranging from $153.80 to $160.00.
• Following these transactions, Mata beneficially owns 3,666 ADS.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider selling, even though it was executed under a pre-planned Rule 10b5-1 trading plan.

Negatives

• Insider selling activity, while conducted under a pre-arranged plan, can sometimes be perceived negatively by the market.

Risks

• The sales were conducted under a Rule 10b5-1 plan, which is designed to mitigate insider trading concerns, but the act of selling by a key executive could still be interpreted as a lack of confidence in near-term stock performance by some investors.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common for executives managing their personal portfolios and complying with trading regulations. However, the volume and timing relative to company news can influence market perception.

Stakeholder Impact

• Shareholders may view insider selling, even under a 10b5-1 plan, with caution, potentially leading to short-term price pressure.
• The company's management team continues to hold shares, indicating ongoing commitment.

Key Dates

Recommendation

The filing reports routine insider sales under a pre-established trading plan, which is a standard practice and does not inherently signal a change in the company's fundamental outlook. While insider selling can be a negative signal, the structured nature of the sale under Rule 10b5-1 mitigates concerns about non-public information. Therefore, a 'hold' recommendation is appropriate pending further company-specific developments.

Keywords

Belite Bio, BLTE, Form 4, Insider Trading, Rule 10b5-1, ADS Sale, Nathan L. Mata, Chief Scientific Officer, Securities Transaction